Pro-Cure has a pipeline agreement with the University of York and Yorkshire Cancer Research which assigns all IP generated by the YCR Cancer Research Unit to the Company.

The Company already has a strong patent portfolio relating to prostate drug targets, second medical use, prostate cancer stem cells models and the isolation of cancer stem cells. It also owns IP relating to baculovirus gene therapy vector technology. With current research, Pro-Cure is likely to generate significantly more intellectual property.